Form 4: AIM ImmunoTech Director Converts Preferred to Common Stock

AIM ImmunoTech Director David I. Chemerow converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock.

Summary

• David I. Chemerow, a Director of AIM ImmunoTech Inc. (AIM), reported a conversion of securities.
• On March 12, 2026, Chemerow converted 25 shares of Series G Convertible Preferred Stock.
• This conversion resulted in the acquisition of 25,000 shares of AIM ImmunoTech Common Stock.
• The conversion rate is 1,000 shares of common stock per whole preferred share, effectively $1.00 per common share.
• Following this transaction, Chemerow beneficially owns 28,441 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director converting preferred shares into common stock suggests confidence in the company's future performance and common stock valuation.

Positives

• Director David I. Chemerow converted preferred stock into common stock, increasing his direct ownership of common shares by 25,000.
• The conversion at an effective price of $1.00 per common share indicates a potential belief in the common stock's value.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider conversions, particularly from preferred to common stock, can be interpreted by the market as a signal of confidence from company leadership regarding the future prospects and valuation of the common equity.

Related Party Transactions

• Director David I. Chemerow converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of Common Stock.

Stakeholder Impact

• Shareholders may interpret the director's conversion of preferred stock into common stock as a positive signal of insider confidence in the company's future.

Key Dates

Recommendation

The conversion of preferred stock to common stock by a director, while not an open market purchase, indicates a commitment to the common equity and can be seen as a vote of confidence. This action alone does not warrant a 'buy' recommendation without further fundamental analysis, but it supports a 'hold' position for existing investors and suggests potential for new investors to consider further due diligence.

Keywords

AIM ImmunoTech, AIM, Form 4, insider transaction, stock conversion, director, common stock, preferred stock, beneficial ownership